Acute Leukemias IX pp 363-365 | Cite as
Biology Based Treatment Strategies for Acute Myeloid Leukemia
Abstract
In the past few years increasing insights into the pathogenesis and biology of acute myeloid leukemia have been gained. These insights reveal, that the clinical picture of acute myeloid leukemia (AML) includes a variety of different subtypes which vary in their biology but also in their sensitivity to chemotherapy and treatment response [1–3]. Based on cytogenetic and molecular analyses three major groups of AML subtypes can be discriminated. One comprises AML with balanced chromosomal aberrations, such as t(18;21), inv(16) and t(15;17). The second group includes cases with unbalanced, mostly numeric chromosomal aberrations frequently involving chromosomes 5,7 and 8. The third group consists of patients with no detectable abnormalities (Fig. 1).These three groups have different treatment outcomes and are hence considered to indicate prognosis.
Keywords
Acute Myeloid Leukemia Cytogenetic Abnormality Acute Myeloid Leukemia Blast Acute Myeloid Leukemia Subtype Numeric Chromosomal AberrationPreview
Unable to display preview. Download preview PDF.
References
- 1.Rigal F, Stoppa A-M, Marit G, Molina L, Michallet M., Maraninchi D, Attal M, and Reiffers J. (1995) Prognostic significance of karyotype in de novo adult acute myelogenous leukemia. Leukemia (Baltimore) 9: 1491–1498.Google Scholar
- 2.Mrózek K, Heinonen K, de la Chapelle A et al. (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol. 24:17–31.Google Scholar
- 3.Stasi R, Del Poeta G, Masi M et al. (1993) Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet. Cytogenet. 167:28–34Google Scholar
- 4.Schoch C, Haferlach T, Haase D et al. (2001) Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients. Br J Haematol. 112:118–126.PubMedCrossRefGoogle Scholar
- 5.Büchner T, Hiddemann W, Wörmann B et al. (1999) Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood 93:4116–245.PubMedGoogle Scholar
- 6.Hoyle CF, de Bastos M, Wheatley K, et al. (1989) AML associated with previous cytotoxic therapy. MDS or myelo-proliferative disorders: results from the MRC′s 9th AML trial. British Journal of Haematology 72:45–53.PubMedCrossRefGoogle Scholar
- 7.Bishop JF, Matthews JP, Young GA et al. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710–7.PubMedGoogle Scholar
- 8.Weick JK, Kopecky KJ, Appelbaum FR et al. (1996) A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Study Group. Blood 88:2841–51.PubMedGoogle Scholar
- 9.Mayer RJ, Davis RB, Schiffer CA et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine 6:896–942.CrossRefGoogle Scholar
- 10.Bloomfield C, Lawrence D, Byrd J et al. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research 58; 4173–4179PubMedGoogle Scholar